Download the Bivatop® 200 LA Swine Leaflet

Product Information Sheet

Product Description

Bivatop® 200 LA is approved for use in pigs and is indicated in the treatment of:

  • Erysipelas (diamond skin disease)
  • Pneumonia
  • Leptospirosis
  • Mastitis
  • Bacterial enteritis (scours, colibacillosis)
  • Pneumonia
  • Navel/joint-ill and wound infections

Aids in the control and prevention of:

  • Bacterial respiratory infections associated with transport or shipping
  • MMA (metritis-mastitis-agalactia) syndrome in sows
  • Scours in suckling piglets
  • Post-operative and post-parturient infections

Features & Benefits

Bivatop® 200 LA broad spectrum antibiotic – achieves rapid results with less tissue damage.1,2

But that’s not the only reason to reach for it.
Bivatop® 200 LA’s SELECTCARRIER™ also achieves

  • High serum concentration1
  • Long duration (over 3 to 5 days)
  • Less muscle damage2

Dosage Information

  • Piglets less than 2 kg body mass: 0,5 ml Bivatop® 200 LA subcutaneously behind the ear.
  • Piglets 2 to 10 kg body mass: 1 ml subcutaneously behind the ear.
  • Pigs in excess of 10 kg: 1 ml/ 10 kg body mass by deep intramuscular injection. Administer a maximum of 5 ml per injection site.

A single intramuscular or subcutaneous injection of 1 ml Bivatop® 200 LA/ 10 kg body mass equivalent to 20 mg oxytetracycline/ kg body mass is indicated to provide sustained antibiotic action over 3 to 5 days for the prevention or treatment of the susceptible disease condition of pigs where re-treatment is impractical due to various animal husbandry reasons. However in more chronic disease conditions a second treatment 48 to 72 hours following the first treatment may be administered.
Withdrawal period: The meat of treated animals may not be used for human consumption within 28 days, after the last treatment.


1. In a study done. Data on file. Ingelheim Pharmaceuticals (Pty) Ltd, South Africa. Animal Health Division.

2. Data on file. Ingelheim Pharmaceuticals (Pty) Ltd, South Africa. Animal Health Division.